6to2
From Proteopedia
(Difference between revisions)
| Line 1: | Line 1: | ||
==Crystal structure of CYP154C5 from Nocardia farcinica in complex with 5alpha-Androstan-3-one== | ==Crystal structure of CYP154C5 from Nocardia farcinica in complex with 5alpha-Androstan-3-one== | ||
| - | <StructureSection load='6to2' size='340' side='right'caption='[[6to2]]' scene=''> | + | <StructureSection load='6to2' size='340' side='right'caption='[[6to2]], [[Resolution|resolution]] 2.00Å' scene=''> |
== Structural highlights == | == Structural highlights == | ||
| - | <table><tr><td colspan='2'>Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=6TO2 OCA]. For a <b>guided tour on the structure components</b> use [ | + | <table><tr><td colspan='2'>[[6to2]] is a 2 chain structure with sequence from [https://en.wikipedia.org/wiki/Nocfa Nocfa]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=6TO2 OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=6TO2 FirstGlance]. <br> |
| - | </td></tr><tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[ | + | </td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=CL:CHLORIDE+ION'>CL</scene>, <scene name='pdbligand=HEM:PROTOPORPHYRIN+IX+CONTAINING+FE'>HEM</scene>, <scene name='pdbligand=NQ8:(5~{S},8~{S},9~{S},10~{S},13~{S},14~{S})-10,13-dimethyl-1,2,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydrocyclopenta[a]phenanthren-3-one'>NQ8</scene></td></tr> |
| + | <tr id='gene'><td class="sblockLbl"><b>[[Gene|Gene:]]</b></td><td class="sblockDat">NFA_53110 ([https://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&srchmode=5&id=247156 NOCFA])</td></tr> | ||
| + | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=6to2 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6to2 OCA], [https://pdbe.org/6to2 PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=6to2 RCSB], [https://www.ebi.ac.uk/pdbsum/6to2 PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=6to2 ProSAT]</span></td></tr> | ||
</table> | </table> | ||
| + | <div style="background-color:#fffaf0;"> | ||
| + | == Publication Abstract from PubMed == | ||
| + | CYP154C5 from Nocardia farcinica is a P450 monooxygenase able to hydroxylate a range of steroids with high regio- and stereoselectivity at the 16a-position. Using protein engineering and substrate modifications based on the crystal structure of CYP154C5, an altered regioselectivity of the enzyme in steroid hydroxylation had been achieved. Thus, conversion of progesterone by mutant CYP154C5 F92A resulted in formation of the corresponding 21-hydroxylated product 11-deoxycorticosterone in addition to 16alpha-hydroxylation. Using MD simulation, this altered regioselectivity appeared to result from an alternate binding mode of the steroid in the active site of mutant F92A. MD simulation further suggested that water entrance to the active site caused higher uncoupling in this mutant. Moreover, exclusive 15alpha-hydroxylation was observed for wild-type CYP154C5 in the conversion of 5a-androstan-3-one, lacking an oxy-functional group at C17. Overall, our data give valuable insight into the structure-function relationship of this cytochrome P450 monooxygenase for steroid hydroxylation. | ||
| + | |||
| + | CYP154C5 Regioselectivity in Steroid Hydroxylation Explored by Substrate Modifications and Protein Engineering.,Bracco P, Wijma HJ, Nicolai B, Rodriguez Buitrago JA, Klunemann T, Vila A, Schrepfer P, Blankenfeldt W, Janssen DB, Schallmey A Chembiochem. 2020 Nov 4. doi: 10.1002/cbic.202000735. PMID:33145893<ref>PMID:33145893</ref> | ||
| + | |||
| + | From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br> | ||
| + | </div> | ||
| + | <div class="pdbe-citations 6to2" style="background-color:#fffaf0;"></div> | ||
| + | == References == | ||
| + | <references/> | ||
__TOC__ | __TOC__ | ||
</StructureSection> | </StructureSection> | ||
[[Category: Large Structures]] | [[Category: Large Structures]] | ||
| - | [[Category: Blankenfeldt W]] | + | [[Category: Nocfa]] |
| - | [[Category: Kluenemann T]] | + | [[Category: Blankenfeldt, W]] |
| - | [[Category: Rodriguez A]] | + | [[Category: Kluenemann, T]] |
| - | [[Category: Schallmey A]] | + | [[Category: Rodriguez, A]] |
| + | [[Category: Schallmey, A]] | ||
| + | [[Category: Cytochrome p450]] | ||
| + | [[Category: Oxidoreductase]] | ||
| + | [[Category: Oxidoreductase-substrate complex]] | ||
| + | [[Category: Steroid binding]] | ||
| + | [[Category: Steroid hydroxylating monooxygenase]] | ||
Revision as of 10:42, 31 March 2021
Crystal structure of CYP154C5 from Nocardia farcinica in complex with 5alpha-Androstan-3-one
| |||||||||||
